PURPOSE: To evaluate the associations between visual acuity and self-reported visual function; visual acuity and health-related quality of life (QoL) metrics; a summary measure of self-reported visual function and health-related QoL; and individual domains of self-reported visual function and health-related QoL in patients with uveitis. METHODS:Best-corrected visual acuity, vision-related functioning as assessed by the NEI VFQ-25, and health-related QoL as assessed by the SF-36 and EuroQoL EQ-5D questionnaires were obtained at enrollment in a clinical trial of uveitis treatments. Multivariate regression and Spearman correlations were used to evaluate associations between visual acuity, vision-related function, and health-related QoL. RESULTS: Among the 255 patients, median visual acuity in the better-seeing eyes was 20/25, the vision-related function score indicated impairment (median, 60), and health-related QoL scores were within the normal population range. Better visual acuity was predictive of higher visual function scores (P ≤ 0.001), a higher SF-36 physical component score, and a higher EQ-5D health utility score (P < 0.001). The vision-specific function score was predictive of all general health-related QoL (P < 0.001). The correlations between visual function score and general quality of life measures were moderate (ρ = 0.29-0.52). CONCLUSIONS: The vision-related function score correlated positively with visual acuity and moderately positively with general QoL measures. Cost-utility analyses relying on changes in generic healthy utility measures will be more likely to detect changes when there are clinically meaningful changes in vision-related function, rather than when there are only changes in visual acuity. (ClinicalTrials.gov number, NCT00132691.).
RCT Entities:
PURPOSE: To evaluate the associations between visual acuity and self-reported visual function; visual acuity and health-related quality of life (QoL) metrics; a summary measure of self-reported visual function and health-related QoL; and individual domains of self-reported visual function and health-related QoL in patients with uveitis. METHODS: Best-corrected visual acuity, vision-related functioning as assessed by the NEI VFQ-25, and health-related QoL as assessed by the SF-36 and EuroQoL EQ-5D questionnaires were obtained at enrollment in a clinical trial of uveitis treatments. Multivariate regression and Spearman correlations were used to evaluate associations between visual acuity, vision-related function, and health-related QoL. RESULTS: Among the 255 patients, median visual acuity in the better-seeing eyes was 20/25, the vision-related function score indicated impairment (median, 60), and health-related QoL scores were within the normal population range. Better visual acuity was predictive of higher visual function scores (P ≤ 0.001), a higher SF-36 physical component score, and a higher EQ-5D health utility score (P < 0.001). The vision-specific function score was predictive of all general health-related QoL (P < 0.001). The correlations between visual function score and general quality of life measures were moderate (ρ = 0.29-0.52). CONCLUSIONS: The vision-related function score correlated positively with visual acuity and moderately positively with general QoL measures. Cost-utility analyses relying on changes in generic healthy utility measures will be more likely to detect changes when there are clinically meaningful changes in vision-related function, rather than when there are only changes in visual acuity. (ClinicalTrials.gov number, NCT00132691.).
Authors: Li Ming Dong; Ashley L Childs; Carol M Mangione; Eric B Bass; Neil M Bressler; Barbara S Hawkins; Marta J Marsh; Päivi Miskala; Harrris A Jaffee; Lee A McCaffrey Journal: Am J Ophthalmol Date: 2004-07 Impact factor: 5.258
Authors: Sheila T Angeles-Han; Steven Yeh; Courtney McCracken; Kirsten Jenkins; Daneka Stryker; Erica Myoung; Larry B Vogler; Kelly Rouster-Stevens; Scott R Lambert; Melanie J Harrison; Sampath Prahalad; Carolyn Drews-Botsch Journal: Arthritis Care Res (Hoboken) Date: 2015-11 Impact factor: 4.794
Authors: John Sheppard; Avani Joshi; Keith A Betts; Stacie Hudgens; Samir Tari; Naijun Chen; Martha Skup; Andrew D Dick Journal: JAMA Ophthalmol Date: 2017-06-01 Impact factor: 7.389
Authors: Rupali K Naik; Katharine S Gries; Anne M Rentz; Jonathan W Kowalski; Dennis A Revicki Journal: Qual Life Res Date: 2013-05-05 Impact factor: 4.147
Authors: Sapna S Gangaputra; Craig W Newcomb; Marshall M Joffe; Kurt Dreger; Hosne Begum; Pichaporn Artornsombudh; Siddharth S Pujari; Ebenezer Daniel; H Nida Sen; Eric B Suhler; Jennifer E Thorne; Nirali P Bhatt; C Stephen Foster; Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum; Grace A Levy-Clarke; John H Kempen Journal: Am J Ophthalmol Date: 2019-07-22 Impact factor: 5.258
Authors: Jennifer Rose-Nussbaumer; N Venkatesh Prajna; K Tiruvengada Krishnan; Jeena Mascarenhas; Revathi Rajaraman; Muthiah Srinivasan; Anita Raghavan; Catherine E Oldenburg; Kieran S O'Brien; Kathryn J Ray; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya; Jeremy D Keenan Journal: JAMA Ophthalmol Date: 2015-06 Impact factor: 7.389